Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENOSYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENOSYL.
AMIKACIN SULFATE vs GENOSYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic